288 related articles for article (PubMed ID: 29725996)
1. Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model-Support for a Biologics License Application Submission: Part I.
Martinez JM; Brunet A; Hurbin F; DiCioccio AT; Rauch C; Fabre D
Clin Pharmacokinet; 2019 Jan; 58(1):101-113. PubMed ID: 29725996
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II.
Nicolas X; Djebli N; Rauch C; Brunet A; Hurbin F; Martinez JM; Fabre D
Clin Pharmacokinet; 2019 Jan; 58(1):115-130. PubMed ID: 29725997
[TBL] [Abstract][Full Text] [Related]
3. Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.
Djebli N; Martinez JM; Lohan L; Khier S; Brunet A; Hurbin F; Fabre D
Clin Pharmacokinet; 2017 Oct; 56(10):1155-1171. PubMed ID: 28063030
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients.
Shen T; James DE; Krueger KA
Pharm Res; 2017 Jan; 34(1):185-192. PubMed ID: 27822850
[TBL] [Abstract][Full Text] [Related]
5. Combined Semi-mechanistic Target-Mediated Drug Disposition and Pharmacokinetic-Pharmacodynamic Models of Alirocumab, PCSK9, and Low-Density Lipoprotein Cholesterol in a Pooled Analysis of Randomized Phase I/II/III Studies.
Nolain P; Djebli N; Brunet A; Fabre D; Khier S
Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):789-802. PubMed ID: 35974290
[TBL] [Abstract][Full Text] [Related]
6. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
Gibbs JP; Doshi S; Kuchimanchi M; Grover A; Emery MG; Dodds MG; Gibbs MA; Somaratne R; Wasserman SM; Blom D
J Clin Pharmacol; 2017 May; 57(5):616-626. PubMed ID: 27861991
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/LDL-C and exposure-response analysis of tafolecimab in Chinese hypercholesterolemia patients: Results from phase I, II, and III studies.
Yan S; Zhao X; Xie Q; Du W; Ma Q; Zhu T; Deng H; Qian L; Zheng S; Cui Y
Clin Transl Sci; 2023 Dec; 16(12):2791-2803. PubMed ID: 37877498
[TBL] [Abstract][Full Text] [Related]
8. A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development.
Udata C; Garzone PD; Gumbiner B; Joh T; Liang H; Liao KH; Williams JH; Meng X
J Clin Pharmacol; 2017 Jul; 57(7):855-864. PubMed ID: 28181260
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
10. Alternative Treatment Regimens With the PCSK9 Inhibitors Alirocumab and Evolocumab: A Pharmacokinetic and Pharmacodynamic Modeling Approach.
Scherer N; Dings C; Böhm M; Laufs U; Lehr T
J Clin Pharmacol; 2017 Jul; 57(7):846-854. PubMed ID: 28263403
[TBL] [Abstract][Full Text] [Related]
11. Population PK/PD modeling of low-density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti-PCSK9 monoclonal antibody.
Wang EQ; Kaila N; Plowchalk D; Gibiansky L; Yunis C; Sweeney K
CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):2013-2026. PubMed ID: 37994400
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia.
Kuchimanchi M; Grover A; Emery MG; Somaratne R; Wasserman SM; Gibbs JP; Doshi S
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):505-522. PubMed ID: 29736889
[TBL] [Abstract][Full Text] [Related]
13. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
[TBL] [Abstract][Full Text] [Related]
14. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD
Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis.
Koren MJ; Roth EM; McKenney JM; Gipe D; Hanotin C; Ferrand AC; Wu R; Dufour R
Postgrad Med; 2015 Mar; 127(2):125-32. PubMed ID: 25609019
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.
Bays HE; Rosenson RS; Baccara-Dinet MT; Louie MJ; Thompson D; Hovingh GK
Cardiovasc Drugs Ther; 2018 Apr; 32(2):175-180. PubMed ID: 29627892
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
Okere AN; Serra C
Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
[TBL] [Abstract][Full Text] [Related]
19. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of alirocumab for the treatment of hypercholesterolemia.
Farnier M
Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1307-23. PubMed ID: 26563849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
